Aurinia Pharmaceuticals (AUPH) Says Voclosporin Achieves Primary, Secondary Endpoints in Phase IIb Study for LN

September 29, 2016 4:56 PM EDT
Get Alerts AUPH Hot Sheet
Trade AUPH Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (TSX:AUP) (“Aurinia” or the “Company”) a clinical stage biopharmaceutical company focused on the global immunology market, today announced that in addition to voclosporin (23.7 mg BID) achieving its primary endpoint of Complete Remission (CR) at 24 weeks, both doses of voclosporin when added to the current standard of care of Mycophenolate Mofetil (MMF) and a forced oral corticosteroid taper have met all 24-week pre-specified secondary endpoints vs the control group. These pre-specified endpoints include: Partial Remission (PR), which is measured by a ≥50% reduction in UPCR with no concomitant use of rescue medication; time to CR and PR; reduction in Systemic Lupus Erythematosus Disease Activity Index or SLEDAI score; and reduction in UPCR over the 24-week treatment period.

Pre-specified Secondary Endpoint Control Low Dose VCS

(23.7mg BID)

High Dose VCS

(39.5mg BID)

Time to Complete Remission (TTCR) [median] Not achieved 19.7 weeks 23.4 weeks
p<.001 p=.001
Partial Remission (as measured by UPCR reduction of ≥ 50% from baseline) 49% 70% 66%
p=.007 p=.024
Time to Partial Remission (TTPR) [median] 6.6 weeks 4.1 weeks 4.4 weeks
p=.002 p=.003
SLEDAI Reduction -4.5 -6.3 -7.1
p=.003 p=.003
Reduction in UPCR -2.216 mg/mg -3.769 mg/mg -2.792 mg/mg
p<.001 p=.006

All p-values are vs control

The AURA-LV study remains ongoing to its 48-week endpoint upon which similar and additional secondary analysis will be analysed and presented early next year.

“We are thrilled by the results of the AURA study and voclosporin’s potential to shift the treatment paradigm for active lupus nephritis,” said Charles Rowland, CEO of Aurinia. “The ability to get more patients into remission and in a shorter period time than the current standard of care can have a significant impact on the long-term outcomes for these patients.”

“LN is a serious and devastating disease that can severely impact a patient’s life,” said William Pendergraft, MD, PhD, Assistant Professor of Medicine in the Division of Nephrology & Hypertension, at the University of North Carolina and a Principal Investigator in the study. “Voclosporin has demonstrated it can nearly double the number of patients that achieve Complete Remission in the presence of very low corticosteroid exposure. Based on these data, I believe this drug has the potential to significantly improve the long-term prognosis of my patients afflicted with LN and could become an integral component of the standard of care.”

The Company will present the full efficacy (including pre-specified and ad hoc sub-analyses) and comprehensive safety data during a webcast presentation to be held at 8:00am ET. A link to the live webcast and slides will be available on the Investors section of the Company’s website at

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Hot Corp. News, Hot FDA News

Add Your Comment